ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2794

Sustained Complete Remission in Lupus Nephritis

Rattapol Pakchotanon1, Dafna D. Gladman2, Jiandong Su2 and Murray Urowitz3, 1Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Rheumatology, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 3Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: death, Lupus nephritis, remission and transplantation

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The durability of renal remission might be a predictor of good long-term renal outcome and survival in patients with lupus nephritis (LN). We aimed to examine the predictors of long-term outcomes in patients with LN who achieve sustained complete remission.

Methods: We reviewed patients with active LN at a single center Lupus Clinic in which patients had been followed prospectively between 1970 and December 2015. We identified the patients who had a minimum of 5 years of follow-up after the complete renal remission (CR) (defined as proteinuria < 500 mg/24 hours or urine protein creatinine ratio < 0.5 and inactive urine sediment). We compared the outcomes of patients who achieved sustained CR, for a minimum of 5 years (group A) with those less than 5 years (group B). The outcomes were mortality, damage (measured by the SLICC/ACR damage index (SDI)), renal flare (any presence of cast, proteinuria, pyuria or hematuria after CR), end stage renal disease (dialysis or transplant) (ESRD) or estimated glomerular filtration rate (eGFR) < 50 mL/min, doubling of serum creatinine, and infection during 20 years after CR. Cox proportional regression models were constructed to identify the predictors of the outcomes in multivariate models controlling for gender, age, disease duration, ethnicity, hypertension and treatment for each outcomes.  

Results: A total of 345 patients were identified, 132 patients in group A and 213 patients in group B.  Most of patients were female (85%). Mean age at the diagnosis of LN was 33.94±12.85 years in group A and 31.75±11.41 years in group B. The duration between active LN and CR was 1.04±1.53 years in group A and 1.46±1.88 years in group B (P=0.03). The duration of CR in group A was 11.76 ± 7.34 years but only 1.24 ± 1.24 years in group B (P< 0.001). Death, increasing of renal SDI, renal flare, renal transplantation, ESRD or eGFR < 50 mL/min, and doubling of serum creatinine in group A were significantly lower than group B (Table 1).  Multivariate analysis revealed that group A were at a lower risk of death (hazard ratio (HR)=0.20; 95% confidence interval (CI), 0.07-0.61; P=0.004), increasing of renal SDI (HR= 0.41; 95% CI, 0.21-0.76; P=0.01), developing ESRD or eGFR < 50 mL/min (HR= 0.27; 95% CI, 0.12-0.61; P=0.001), and doubling of serum creatinine (HR= 0.29; 95% CI, 0.14-0.61; P=0.001) compared with group B.

Conclusion: Sustained complete remission for at least 5 years is an independent predictor of better prognosis in lupus nephritis in terms of reduced mortality, chronic kidney disease and end stage renal disease. Table 1 Outcomes over 20 years after complete renal remission in lupus nephritis

Group A (N=132)

Group B (N=213)

P

Death, n (%)

5 (3.8)

26 (12.2)

0.01

Increasing of SDI, n (%)

73 (55.3)

134 (62.6)

0.16

Increasing of renal SDI, n (%)

13 (9.8)

53 (24.9)

<0.001

Renal flare, n (%)

61 (46.2)

213 (100)

<0.001

Renal transplantation, n (%)

2 (1.5)

15 (7)

0.02

ESRD or eGFR < 50 mL/min, n (%)

7 (5.3)

37 (17.4)

0.001

Doubling of serum creatinine, n (%)

19 (9.8)

45 (21.1)

0.005

Group A=patients who achieved sustained complete remission, a minimum of 5 years; Group B= patients who achieved sustained complete remission, less than 5 years; SDI= SLICC/ACR damage index; ESRD= end stage renal disease; eGFR=estimated glomerular filtration rate.


Disclosure: R. Pakchotanon, None; D. D. Gladman, None; J. Su, None; M. Urowitz, None.

To cite this abstract in AMA style:

Pakchotanon R, Gladman DD, Su J, Urowitz M. Sustained Complete Remission in Lupus Nephritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/sustained-complete-remission-in-lupus-nephritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sustained-complete-remission-in-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology